Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

JAZZ-REDX-acq-KRAS-UK

More Like This

PR Newswire associated0

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

PR Newswire associated0

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

PR Newswire associated0

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

PR Newswire associated0

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

PR Newswire associated0

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference